Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy

First clinical observations of HER2 specific [111In]ABY-025 metastatic detection capability in females with metastatic breast cancer

Dan Sandberg, Anders Wennborg, Joachim Feldwisch, Vladimir Tolmachev, Jörgen Carlsson, Ulrike Garske, Jens Sörensen and Henrik Lindman
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 220;
Dan Sandberg
1NM & PET, Uppsala University Hospital, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anders Wennborg
2Affibody AB, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joachim Feldwisch
2Affibody AB, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladimir Tolmachev
3Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jörgen Carlsson
3Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrike Garske
1NM & PET, Uppsala University Hospital, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jens Sörensen
1NM & PET, Uppsala University Hospital, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henrik Lindman
4Oncology, Uppsala University Hospital, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 53 no. supplement 1 220

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online November 4, 2014.

Copyright & Usage 
© 2012

Author Information

  1. Dan Sandberg1,
  2. Anders Wennborg2,
  3. Joachim Feldwisch2,
  4. Vladimir Tolmachev3,
  5. Jörgen Carlsson3,
  6. Ulrike Garske1,
  7. Jens Sörensen1 and
  8. Henrik Lindman4
  1. 1NM & PET, Uppsala University Hospital, Uppsala, Sweden
  2. 2Affibody AB, Stockholm, Sweden
  3. 3Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden
  4. 4Oncology, Uppsala University Hospital, Uppsala, Sweden

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: November 2014 to April 2025

AbstractFullPdf
Nov 2014100
Dec 2014200
Mar 20151100
May 2015500
Jun 2015600
Jul 2015200
Sep 20151400
Nov 2015400
Mar 2016100
May 2016200
Jun 2016100
Aug 2016100
Sep 2016400
Oct 2016200
Nov 2016400
Dec 2016100
Jan 2017300
Feb 2017100
Mar 2017200
Apr 20172200
May 2017100
Jun 2017200
Jul 2017200
Aug 2017100
Sep 2017100
Oct 2017100
Dec 2017200
Mar 2018100
Apr 2018200
Jul 2018200
Aug 2018100
Sep 2018700
Nov 2018200
Feb 2019200
Mar 2019100
Apr 2019600
May 2019500
Aug 2019200
Sep 2019100
Nov 2019600
Dec 2019300
Jan 2020300
Feb 2020500
Mar 20201500
Apr 2020800
May 2020200
Jul 2020400
Aug 20201900
Sep 20202700
Oct 2020900
Nov 20201600
Dec 20201100
Jan 2021100
Feb 2021500
Mar 2021900
Apr 2021800
May 2021500
Jun 2021200
Jul 20211700
Aug 20213500
Sep 20211200
Oct 20211000
Nov 20216600
Dec 20214000
Jan 20226900
Feb 20222200
Mar 20221100
Apr 2022700
May 20222400
Jun 2022300
Jul 2022400
Aug 20221100
Sep 2022100
Oct 2022300
Nov 2022100
Dec 2022200
Jan 2023100
Mar 2023500
Apr 2023300
May 2023300
Jun 2023300
Jul 2023300
Aug 2023100
Sep 2023500
Oct 2023500
Nov 2023100
Dec 2023600
Jan 2024400
Feb 2024700
Mar 2024400
Apr 2024100
May 2024300
Jun 2024300
Aug 2024800
Sep 2024400
Oct 2024500
Nov 2024300
Dec 2024500
Jan 2025100
Feb 20251000
Mar 2025700
Apr 2025600
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 53, Issue supplement 1
May 2012
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
First clinical observations of HER2 specific [111In]ABY-025 metastatic detection capability in females with metastatic breast cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
First clinical observations of HER2 specific [111In]ABY-025 metastatic detection capability in females with metastatic breast cancer
Dan Sandberg, Anders Wennborg, Joachim Feldwisch, Vladimir Tolmachev, Jörgen Carlsson, Ulrike Garske, Jens Sörensen, Henrik Lindman
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 220;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
First clinical observations of HER2 specific [111In]ABY-025 metastatic detection capability in females with metastatic breast cancer
Dan Sandberg, Anders Wennborg, Joachim Feldwisch, Vladimir Tolmachev, Jörgen Carlsson, Ulrike Garske, Jens Sörensen, Henrik Lindman
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 220;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy

  • Generation and validation of a surrogate truth model for xSPECT Bone concordance analysis
  • Investigation of volume-of-interest (VOI) definition methods for estimating organ activity concentrations in quantitative SPECT (QSPECT)
  • SUVmax of Normal Tissues in Pediatric and Adult Patients on FDG PET/MR
Show more Oncology: Basic, Translational & Therapy

Basic Science (Oncology): Tumor Characterization & Microenvironment

  • Quantitative analysis of [18F]FMISO PET for tumor hypoxia: Correlation with results using immunohistochemistry
  • Kras mutation causes increased 18F-FDG uptake in experimental models of colorectal cancer
Show more Basic Science (Oncology): Tumor Characterization & Microenvironment

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire